UCB S.A.’s ambitions to be a key player in gene therapy have advanced with the acquisition of fellow Belgian firm Handl Therapeutics and an R&D collaboration with Lacerta Therapeutics Inc of the US.
UCB Acquires Belgian Gene Therapy Firm Handl
Also Inks Deal With Lacerta
The Brussels-based company has leant on its local knowledge to snap up Leuven-headquartered biotech Handl and its proprietary AAV capsid technology platform.
More from Deals
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.